This research study is currently not recruiting patients.

A Multi-Center Randomized Placebo-Controlled Double-Blind Study To Confirm Efficacy And Safety Of Terlipressin In Subjects With Hepatorenal Syndrome Type 1

Brief description of study

The purpose of this randomized, placebo-controlled study is to confirm the efficacy and safety of terlipressin in the treatment of subjects with HRS Type 1 to provide data to support regulatory approval of the New Drug Application (NDA). Efficacy will be assessed through the primary endpoint of verified HRS reversal; other important efficacy parameters will be assessed including short-term durability of verified HRS reversal, magnitude of SCr lowering effect and effects in important subgroups (eg, systemic inflammatory response syndrome [SIRS] subgroup). Safety data will be collected and incorporated into the overall safety assessment of terlipressin. Methodological obstacles encountered in the REVERSE trial that reduced its ability to show statistical significance on the primary endpoint have been addressed in this trial design.

Clinical Study Identifier: s17-01656 Identifier: NCT02770716
Not Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.